Lexicon Pharmaceuticals (NASDAQ:LXRX) was downgraded by stock analysts at JPMorgan Chase & Co. from a “neutral” rating to an “underweight” rating in a research report issued to clients and investors on Wednesday, The Fly reports.

Other research analysts also recently issued research reports about the stock. Zacks Investment Research upgraded shares of Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday. ValuEngine downgraded shares of Lexicon Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, February 2nd. BidaskClub downgraded shares of Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, February 5th. Finally, Wedbush reiterated an “outperform” rating and issued a $38.00 target price on shares of Lexicon Pharmaceuticals in a research note on Thursday, November 30th. Three analysts have rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $28.50.

Lexicon Pharmaceuticals (NASDAQ LXRX) opened at $9.29 on Wednesday. The stock has a market cap of $975.63, a P/E ratio of -7.37 and a beta of 0.24. Lexicon Pharmaceuticals has a 52 week low of $8.07 and a 52 week high of $18.00. The company has a quick ratio of 1.65, a current ratio of 1.66 and a debt-to-equity ratio of 1.09.

In related news, Director Public Equities L.P. Invus acquired 180,727 shares of the stock in a transaction that occurred on Friday, November 17th. The shares were bought at an average price of $10.11 per share, for a total transaction of $1,827,149.97. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 5.77% of the stock is owned by corporate insiders.

Institutional investors have recently modified their holdings of the stock. Artal Group S.A. raised its position in Lexicon Pharmaceuticals by 1.3% in the fourth quarter. Artal Group S.A. now owns 58,274,650 shares of the biopharmaceutical company’s stock worth $575,754,000 after acquiring an additional 756,673 shares during the period. State Street Corp raised its position in Lexicon Pharmaceuticals by 19.9% in the second quarter. State Street Corp now owns 1,967,255 shares of the biopharmaceutical company’s stock worth $32,363,000 after acquiring an additional 326,088 shares during the period. Pinnacle Associates Ltd. raised its position in Lexicon Pharmaceuticals by 25.5% in the third quarter. Pinnacle Associates Ltd. now owns 897,045 shares of the biopharmaceutical company’s stock worth $11,025,000 after acquiring an additional 182,215 shares during the period. Kornitzer Capital Management Inc. KS bought a new position in Lexicon Pharmaceuticals in the third quarter worth approximately $9,420,000. Finally, Sector Gamma AS raised its position in Lexicon Pharmaceuticals by 18.4% in the third quarter. Sector Gamma AS now owns 737,453 shares of the biopharmaceutical company’s stock worth $9,063,000 after acquiring an additional 114,798 shares during the period.

ILLEGAL ACTIVITY NOTICE: “JPMorgan Chase & Co. Lowers Lexicon Pharmaceuticals (LXRX) to Underweight” was reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this article on another website, it was illegally copied and republished in violation of international copyright and trademark laws. The original version of this article can be viewed at https://theolympiareport.com/2018/02/14/jpmorgan-chase-co-lowers-lexicon-pharmaceuticals-lxrx-to-underweight.html.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development.

The Fly

Analyst Recommendations for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.